Trial Profile
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2025.
- 25 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
- 01 Nov 2021 Planned End Date changed from 1 Aug 2021 to 1 Aug 2023.